LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System.

Authors:
Boyer D; Hu A; Warrow D; Xavier S; Gonzalez V and 12 more

Journal:
Retina

Publication Year: 2024

DOI:
10.1097/IAE.0000000000003980

PMCID:
PMC10885856

PMID:
37972955

Journal Information

Full Title: Retina

Abbreviation: Retina

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Ophthalmology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"S. E. Tedford, C. L. Croissant, M. Walker, R. Rückert and C. Tedford are all employees/contractors of LumiThera."

Evidence found in paper:

"The LIGHTSITE III study was supported in part by LumiThera, Inc. and the National Eye Institute (Grant #1R43EY025508-03)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025